Does the media favor RVMD or SNY?

In the previous week, Revolution Medicines had 11 more articles in the media than Sanofi. MarketBeat recorded 14 mentions for Revolution Medicines and 3 mentions for Sanofi. Revolution Medicines' average media sentiment score of 0.44 beat Sanofi's score of 0.40 indicating that Revolution Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Sanofi 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger valuation and earnings, GSK or RVMD?

GSK has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GSK $43.07B 2.39 $7.54B $3.85 13.16 Revolution Medicines $11.58M 2,726.16 -$1.13B -$7.07 N/A

Is GSK or RVMD more profitable?

GSK has a net margin of 17.82% compared to Revolution Medicines' net margin of 0.00%. GSK's return on equity of 44.28% beat Revolution Medicines' return on equity. Company Net Margins Return on Equity Return on Assets GSK 17.82% 44.28% 11.49% Revolution Medicines N/A -83.22% -59.06%

Does the media favor GSK or RVMD?

In the previous week, Revolution Medicines had 3 more articles in the media than GSK. MarketBeat recorded 14 mentions for Revolution Medicines and 11 mentions for GSK. GSK's average media sentiment score of 0.53 beat Revolution Medicines' score of 0.44 indicating that GSK is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GSK 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revolution Medicines 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to RVMD or ARGX?

In the previous week, Revolution Medicines had 7 more articles in the media than argenex. MarketBeat recorded 14 mentions for Revolution Medicines and 7 mentions for argenex. argenex's average media sentiment score of 0.52 beat Revolution Medicines' score of 0.44 indicating that argenex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral argenex 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer RVMD or TAK?

Revolution Medicines currently has a consensus target price of $123.72, indicating a potential downside of 16.68%. Given Revolution Medicines' stronger consensus rating and higher possible upside, analysts plainly believe Revolution Medicines is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revolution Medicines 1 Sell rating(s) 1 Hold rating(s) 17 Buy rating(s) 3 Strong Buy rating(s) 3.00 Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media refer more to RVMD or TAK?

In the previous week, Revolution Medicines had 12 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 14 mentions for Revolution Medicines and 2 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.80 beat Revolution Medicines' score of 0.44 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Takeda Pharmaceutical 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Revolution Medicines (RVMD) Competitors

$148.49 -0.74 (-0.50%)

Closing price 04:00 PM Eastern

Extended Trading

$148.00 -0.49 (-0.33%)

As of 07:58 PM Eastern

Compare

RVMD vs. SNY, GSK, ARGX, TAK, and TEVA

Should you buy Revolution Medicines stock or one of its competitors? MarketBeat compares Revolution Medicines with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Revolution Medicines include Sanofi (SNY), GSK (GSK), argenex (ARGX), Takeda Pharmaceutical (TAK), and Teva Pharmaceutical Industries (TEVA). These companies are all part of the "pharmaceutical products" industry.

How does Revolution Medicines compare to Sanofi?

Revolution Medicines (NASDAQ:RVMD) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation.

Revolution Medicines currently has a consensus price target of $123.72, suggesting a potential downside of 16.68%. Sanofi has a consensus price target of $51.00, suggesting a potential upside of 16.23%. Given Sanofi's higher possible upside, analysts clearly believe Sanofi is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	3.00
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47

Sanofi has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	2,726.16	-$1.13B	-$7.07	N/A
Sanofi	$49.35B	2.16	$8.84B	$3.58	12.26

In the previous week, Revolution Medicines had 11 more articles in the media than Sanofi. MarketBeat recorded 14 mentions for Revolution Medicines and 3 mentions for Sanofi. Revolution Medicines' average media sentiment score of 0.44 beat Sanofi's score of 0.40 indicating that Revolution Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sanofi	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 14.0% of Sanofi shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by company insiders. Comparatively, 1.0% of Sanofi shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Sanofi has a net margin of 16.95% compared to Revolution Medicines' net margin of 0.00%. Sanofi's return on equity of 13.39% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
Sanofi	16.95%	13.39%	7.58%

Revolution Medicines has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, Sanofi has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market.

Summary

Revolution Medicines beats Sanofi on 9 of the 17 factors compared between the two stocks.

How does Revolution Medicines compare to GSK?

GSK (NYSE:GSK) and Revolution Medicines (NASDAQ:RVMD) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

15.7% of GSK shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 10.0% of GSK shares are owned by insiders. Comparatively, 7.6% of Revolution Medicines shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

GSK has a net margin of 17.82% compared to Revolution Medicines' net margin of 0.00%. GSK's return on equity of 44.28% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GSK	17.82%	44.28%	11.49%
Revolution Medicines	N/A	-83.22%	-59.06%

GSK has a beta of 0.36, indicating that its stock price is 64% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market.

GSK currently has a consensus target price of $53.00, suggesting a potential upside of 4.58%. Revolution Medicines has a consensus target price of $123.72, suggesting a potential downside of 16.68%. Given GSK's higher probable upside, analysts plainly believe GSK is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GSK	3 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.89
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	3.00

GSK has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GSK	$43.07B	2.39	$7.54B	$3.85	13.16
Revolution Medicines	$11.58M	2,726.16	-$1.13B	-$7.07	N/A

In the previous week, Revolution Medicines had 3 more articles in the media than GSK. MarketBeat recorded 14 mentions for Revolution Medicines and 11 mentions for GSK. GSK's average media sentiment score of 0.53 beat Revolution Medicines' score of 0.44 indicating that GSK is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GSK	5 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revolution Medicines	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

GSK beats Revolution Medicines on 10 of the 17 factors compared between the two stocks.

How does Revolution Medicines compare to argenex?

Revolution Medicines (NASDAQ:RVMD) and argenex (NASDAQ:ARGX) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

argenex has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	2,726.16	-$1.13B	-$7.07	N/A
argenex	$4.25B	12.92	$1.29B	$22.46	39.29

In the previous week, Revolution Medicines had 7 more articles in the media than argenex. MarketBeat recorded 14 mentions for Revolution Medicines and 7 mentions for argenex. argenex's average media sentiment score of 0.52 beat Revolution Medicines' score of 0.44 indicating that argenex is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
argenex	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

argenex has a net margin of 31.31% compared to Revolution Medicines' net margin of 0.00%. argenex's return on equity of 44.37% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
argenex	31.31%	44.37%	37.55%

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by insiders. Comparatively, 2.4% of argenex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Revolution Medicines presently has a consensus target price of $123.72, indicating a potential downside of 16.68%. argenex has a consensus target price of $1,019.50, indicating a potential upside of 15.54%. Given argenex's higher probable upside, analysts plainly believe argenex is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	3.00
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92

Revolution Medicines has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market. Comparatively, argenex has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market.

Summary

argenex beats Revolution Medicines on 10 of the 17 factors compared between the two stocks.

How does Revolution Medicines compare to Takeda Pharmaceutical?

Revolution Medicines (NASDAQ:RVMD) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Takeda Pharmaceutical has a net margin of 4.31% compared to Revolution Medicines' net margin of 0.00%. Takeda Pharmaceutical's return on equity of 11.07% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
Takeda Pharmaceutical	4.31%	11.07%	5.49%

Revolution Medicines currently has a consensus target price of $123.72, indicating a potential downside of 16.68%. Given Revolution Medicines' stronger consensus rating and higher possible upside, analysts plainly believe Revolution Medicines is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	3.00
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Revolution Medicines has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market.

Takeda Pharmaceutical has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	2,726.16	-$1.13B	-$7.07	N/A
Takeda Pharmaceutical	$28.32B	1.77	$1.27B	$0.39	40.45

In the previous week, Revolution Medicines had 12 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 14 mentions for Revolution Medicines and 2 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.80 beat Revolution Medicines' score of 0.44 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Takeda Pharmaceutical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Revolution Medicines beats Takeda Pharmaceutical on 9 of the 17 factors compared between the two stocks.

How does Revolution Medicines compare to Teva Pharmaceutical Industries?

Revolution Medicines (NASDAQ:RVMD) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, valuation, institutional ownership, profitability and risk.

Revolution Medicines currently has a consensus price target of $123.72, suggesting a potential downside of 16.68%. Teva Pharmaceutical Industries has a consensus price target of $41.78, suggesting a potential upside of 25.70%. Given Teva Pharmaceutical Industries' higher probable upside, analysts plainly believe Teva Pharmaceutical Industries is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	3.00
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

In the previous week, Teva Pharmaceutical Industries had 20 more articles in the media than Revolution Medicines. MarketBeat recorded 34 mentions for Teva Pharmaceutical Industries and 14 mentions for Revolution Medicines. Teva Pharmaceutical Industries' average media sentiment score of 1.18 beat Revolution Medicines' score of 0.44 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Teva Pharmaceutical Industries	27 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Revolution Medicines has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market.

Teva Pharmaceutical Industries has a net margin of 9.01% compared to Revolution Medicines' net margin of 0.00%. Teva Pharmaceutical Industries' return on equity of 43.53% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

Teva Pharmaceutical Industries has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	2,726.16	-$1.13B	-$7.07	N/A
Teva Pharmaceutical Industries	$17.26B	2.21	$1.41B	$1.33	24.99

Summary

Teva Pharmaceutical Industries beats Revolution Medicines on 10 of the 17 factors compared between the two stocks.

Get Revolution Medicines News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RVMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RVMD vs. The Competition

Export

Metric	Revolution Medicines	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$31.73B	$3.34B	$6.49B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.57%
P/E Ratio	-21.00	18.61	23.92	23.74
Price / Sales	2,726.16	298.43	507.57	108.00
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	17.59	8.04	10.28	6.78
Net Income	-$1.13B	$23.89M	$3.57B	$337.51M
7 Day Performance	-9.28%	-5.97%	-1.43%	-2.72%
1 Month Performance	4.71%	2.78%	3.27%	1.87%
1 Year Performance	261.38%	36.26%	23.37%	26.60%

Revolution Medicines Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RVMD Revolution Medicines	2.1238 of 5 stars	$148.49 -0.5%	$123.72 -16.7%	+263.2%	$31.73B	$11.58M	N/A	250
SNY Sanofi	4.4205 of 5 stars	$42.96 -1.6%	$51.00 +18.7%	-10.8%	$105.87B	$49.35B	12.00	74,846	Positive News
GSK GSK	2.6626 of 5 stars	$49.23 -2.6%	$53.00 +7.6%	+25.1%	$102.56B	$32.78B	12.79	66,841	Dividend Cut
ARGX argenex	3.5518 of 5 stars	$836.09 +0.0%	$1,019.50 +21.9%	+52.1%	$51.99B	$4.66B	37.23	1,863	News Coverage
TAK Takeda Pharmaceutical	3.578 of 5 stars	$15.20 -4.8%	N/A	+4.3%	$50.79B	$4.51T	38.96	47,455

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RVMD) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Revolution Medicines (RVMD) Competitors

RVMD vs. SNY, GSK, ARGX, TAK, and TEVA

How does Revolution Medicines compare to Sanofi?

Summary

How does Revolution Medicines compare to GSK?

Summary

How does Revolution Medicines compare to argenex?

Summary

How does Revolution Medicines compare to Takeda Pharmaceutical?

Summary

How does Revolution Medicines compare to Teva Pharmaceutical Industries?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVMD vs. The Competition

Revolution Medicines Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Revolution Medicines (RVMD) Competitors

RVMD vs. SNY, GSK, ARGX, TAK, and TEVA

How does Revolution Medicines compare to Sanofi?

Do analysts recommend RVMD or SNY?

Which has preferable earnings & valuation, RVMD or SNY?

Does the media favor RVMD or SNY?

Do institutionals & insiders hold more shares of RVMD or SNY?

Is RVMD or SNY more profitable?

Which has more volatility & risk, RVMD or SNY?

Summary

How does Revolution Medicines compare to GSK?

Do insiders & institutionals hold more shares of GSK or RVMD?

Is GSK or RVMD more profitable?

Which has more risk & volatility, GSK or RVMD?

Do analysts prefer GSK or RVMD?

Which has stronger valuation and earnings, GSK or RVMD?

Does the media favor GSK or RVMD?

Summary

How does Revolution Medicines compare to argenex?

Which has higher valuation & earnings, RVMD or ARGX?

Does the media refer more to RVMD or ARGX?

Is RVMD or ARGX more profitable?

Do institutionals & insiders have more ownership in RVMD or ARGX?

Do analysts recommend RVMD or ARGX?

Which has more risk & volatility, RVMD or ARGX?

Summary

How does Revolution Medicines compare to Takeda Pharmaceutical?

Is RVMD or TAK more profitable?

Do analysts prefer RVMD or TAK?

Do insiders and institutionals have more ownership in RVMD or TAK?

Which has more volatility and risk, RVMD or TAK?

Which has stronger valuation and earnings, RVMD or TAK?

Does the media refer more to RVMD or TAK?

Summary

How does Revolution Medicines compare to Teva Pharmaceutical Industries?

Do analysts prefer RVMD or TEVA?

Does the media favor RVMD or TEVA?

Do institutionals & insiders hold more shares of RVMD or TEVA?

Which has more risk & volatility, RVMD or TEVA?

Is RVMD or TEVA more profitable?

Which has preferable valuation & earnings, RVMD or TEVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVMD vs. The Competition

Revolution Medicines Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools